finerenone是第一个在糖尿病肾病患者中降低肾脏+CV事件风险的非甾体类选择性盐皮质激素受体拮抗剂。 2021年02月13日讯 /生物谷 ...

这篇综述系统阐述了非甾体盐皮质激素受体拮抗剂(ns-MRA)Finerenone在慢性肾病(CKD)合并2型糖尿病(T2D)患者中的肾脏和心血管保护作用。基于FIDELIO-DKD、FIGARO-DKD和FINEARTS-HF等III期临床试验证据，Finerenone在延缓CKD进展、降低心血管事件风险(特别是心衰住院[HHF])方面展现 ...

本研究针对非糖尿病慢性肾病(CKD)患者蛋白尿管理的临床难题，哈尔滨医科大学附属第一医院肾内科团队开展了一项回顾性研究，评估新型非甾体盐皮质激素受体拮抗剂(MRA)finerenone的疗效与安全性。结果显示，finerenone治疗5个月使24小时尿蛋白(24-h UTP)中位数降低2. ...

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, ...

Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FINE-ONE trial assessed finerenone use by adults ...

Please provide your email address to receive an email when new articles are posted on . For adults with mild heart failure, finerenone was not associated with eGFR benefits compared with placebo.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia ® (finerenone) as a potential treatment for heart ...